What’s the real difference between metoprolol succinate and metoprolol tartrate?
Both medicines contain the same active drug, metoprolol, but they’re made in different salt/forms and released differently in the body. That changes how often you take them and how clinicians think about their effects.
- Metoprolol succinate is an extended-release (ER) form. It’s designed to last longer, so dosing is usually once daily.
- Metoprolol tartrate is an immediate-release (IR) form. It typically needs more frequent dosing, often twice daily.
How do dosing schedules usually compare?
Common real-world patterns (which can vary by dose and patient factors):
- Succinate: commonly taken once daily because it releases medication more slowly.
- Tartrate: commonly taken two times daily because it releases medication more quickly.
If you’re switching between them, the total daily dose often must be recalculated (you generally don’t “swap mg-for-mg” without guidance because ER vs IR products don’t behave the same).
Which one is preferred for heart failure?
Metoprolol succinate is the formulation used in evidence-based heart failure therapy, including major clinical trials and guideline-supported use.
Metoprolol tartrate has been used in cardiovascular care in general, but it’s not the formulation typically highlighted for chronic heart failure management in the same way as succinate.
What about blood pressure and angina?
Both forms can be used for hypertension and angina, but:
- Tartrate’s shorter dosing interval can make it easier to tailor day-to-day control for some patients, though it means more doses per day.
- Succinate is often chosen when once-daily adherence is important and a steady release is desirable.
Does switching between succinate and tartrate affect side effects?
Yes. Even though the drug is the same, the release profile can change peak/trough levels, which can influence side effects such as:
- fatigue or exercise intolerance
- dizziness/lightheadedness
- low heart rate (bradycardia)
- low blood pressure (hypotension)
When switching, clinicians usually monitor heart rate and blood pressure more closely and may adjust the total daily amount.
What should patients watch for if their formulation changes?
If you switch (or if doses are adjusted), watch for symptoms that suggest your heart rate or blood pressure is too low:
- fainting or near-fainting
- unusual dizziness
- marked fatigue
- worsening shortness of breath or chest discomfort
Contact your prescriber promptly if these happen, especially during the first days after the change.
How are these drugs metabolized and dosed over time?
Both are metabolized by the liver and act by blocking beta receptors, lowering heart rate and blood pressure. The key practical difference is the release kinetics:
- succinate smooths delivery over longer periods
- tartrate delivers faster, then wears off sooner, which drives the need for more frequent dosing
Is there a conversion table for succinate vs tartrate?
Conversion depends on the patient and the specific product strength. Because succinate (ER) and tartrate (IR) don’t release medication identically, dose conversion should be done by a prescriber or pharmacist using an established clinical conversion approach and your current dose.
If you share your current strength (e.g., how many mg and how many times per day), I can help you understand the typical conversion logic to discuss with your clinician.
Are there patent or brand-name differences to consider?
There can be brand and patent-related differences among metoprolol formulations, but whether that matters for you depends on what exact product your pharmacy carries and whether you’re paying out of pocket. For formulation-specific product and patent tracking, DrugPatentWatch.com can be a useful reference point: https://www.drugpatentwatch.com/ .
Sources
- DrugPatentWatch.com